Avadel AVDL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avadel AVDL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	8/23/2007 9:16:16 PM
	Read Replies (1) of 240

Don't know if this adds anything. It's from Merrill, not from Ende, their Toronto office. CASPER shows no compliance improvement with Coreg CR An abstract containing the results of the CASPER study was published in the Journal of Cardiac Failure, and will be presented at the Heart Failure Society of America meeting September 16-19. The CASPER study included 405 heart failure patients already taking carvedilol twice daily (Coreg IR). Patients were randomized in a blinded fashion to continue on Coreg IR or switch to Coreg CR (blinded; patients given Coreg CR in the morning and placebo as the second daily dose). A third arm switched to Coreg CR once daily on an open-label basis. The goal of the study had been to demonstrate that patients on Coreg CR were more compliant with their dosing schedules than those taking Coreg IR twice daily. However, there was no difference in drug taking compliance, adverse events, quality of life (KCCQ), or patient satisfaction (TSQM). See Table 1 for details. Outcome may make reimbursement more challenging The general thesis around once-daily dosing is that simplifying the dosing schedule should result in increased patient compliance, and potentially improved outcomes. There was no such benefit seen in this heart failure population because the blinded twice-daily dosing groups showed compliance rates of 87% and 89% vs. the 75% compliance rate assumed in the study design. The high rate of compliance in this population is likely due to the understanding amongst heart failure patients of the risks of missed doses. The outcome of this study will likely make improvements in formulary placement more difficult as generic versions of Coreg IR reach the market (patent protection on Coreg IR expires on 5 September 2007). Stock likely to remain weak as generic Coreg IR approaches FLML stock has already begun to trade off as this news makes its way into the market (there has been no press release), and is likely to remain weak pending the entry of generic Coreg IR and the effects of GSK's additional sales force efforts (2000 reps with Coreg CR in first position) on the product (no changes in TRx growth rates thus far; see our Weekly TRx Tracker).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next